Senior Director, MPN Oncology Discovery

Damora Therapeutics; Waltham (MA); On-site; USD 190,000 - 270,000; Full time

Job summary

Damora Therapeutics in the United States seeks an accomplished scientific leader to establish strategy and direction for its oncology drug discovery portfolio, with emphasis on myeloproliferative neoplasms (MPNs).

The candidate will be a recognized authority on MPN biology with an established record in polycythemia vera, essential thrombocythemia, and myelofibrosis, and will prioritize initiatives while aligning discovery with development goals.

Qualifications

• Ph.D. in Oncology or related field with ≥6 years in industry drug discovery, or Master’s with ≥10 years in industry
• Deep knowledge of myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, myelofibrosis)
• Experience leading cross-functional, matrixed discovery teams
• Track record of go/no-go decisions and establishing program direction
• Experience presenting strategy to senior leadership and external partners
• Strong problem-solving and strategic thinking in fast-paced research environments

Responsibilities

• Set strategy and direction for the MPN and oncology discovery portfolio.
• Lead cross-functional discovery teams across DMPK, non-clinical sciences, translational sciences, and clinical development.
• Represent MPN research externally at conferences and with partners or academic collaborators; communicate strategy and risk to leadership.
• Lead portfolio prioritization, due diligence, and competitive assessments.
• Own authorship and quality of scientific reports and publications.
• Monitor MPN biology developments and translate findings into program direction

Skills

Strategic leadership

Cross-functional collaboration

Drug discovery leadership

Portfolio prioritization

Science communication

Regulatory reporting

Education

Ph.D. in related field

Master's degree in related discipline

Job description

Damora Therapeutics in the United States seeks an accomplished scientific leader to establish strategy and direction for its oncology drug discovery portfolio, with emphasis on myeloproliferative neoplasms (MPNs).

The candidate will be a recognized authority on MPN biology with an established record in polycythemia vera, essential thrombocythemia, and myelofibrosis, and will prioritize initiatives while aligning discovery with development goals.